Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
<h4>Background</h4>Matrix metalloproteinase-9 (MMP-9) contributes to chronic lymphocytic leukemia (CLL) pathology by regulating cell migration and preventing spontaneous apoptosis. It is not known if MMP-9 is involved in CLL cell response to chemotherapy and we address this in the presen...
Saved in:
Main Authors: | Irene Amigo-Jiménez, Elvira Bailón, Estefanía Ugarte-Berzal, Noemí Aguilera-Montilla, José A García-Marco, Angeles García-Pardo |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/2cebfa6706cf4c8e9f6b47ea8fab24e6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008) -
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
by: Federica Frezzato, et al.
Published: (2012) -
Functional and structural phenotyping of cardiomyocytes in the 3D organization of embryoid bodies exposed to arsenic trioxide
by: Paola Rebuzzini, et al.
Published: (2021) -
A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system
by: Lu Y, et al.
Published: (2018) -
Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells
by: Xiong,Xilin, et al.
Published: (2018)